评估用于HIV预防的替诺福韦艾拉酚胺/艾维雷韦栓剂经直肠给药安全性和药代动力学的1期临床试验
MTN-039是一项1期、开放标签、单臂、两剂次研究,评估替诺福韦艾拉酚胺/艾维雷韦(TAF/EVG,20 mg/16 mg)栓剂经直肠给药的安全性、药代动力学和离体药效学。结果显示栓剂安全且耐受良好,直肠组织EVG在2小时达峰后24小时多数样本低于定量下限,而TFV-DP在2剂次后72小时内维持>2000 fmol/百万细胞,离体直肠组织HIV p24抗原中位累积log10在1剂和2剂后各时间点均较基线降低(P < .065和P < .039)。
要点
- TAF/EVG栓剂经直肠给药安全且耐受良好。
- 2剂次后血浆中EVG和TFV中位峰值浓度分别为2.4 ng/mL和4.4 ng/mL。
- 2剂次后直肠组织TFV-DP在72小时内维持>2000 fmol/百万细胞。
核心结论
- TAF/EVG栓剂经直肠给药可实现直肠组织高浓度EVG和TFV-DP、低全身药物暴露,并显示72小时离体抑制HIV感染。
研究设计与样本
- MTN-039是一项1期、开放标签、单臂、两剂次研究,每名受试者直肠给药1剂和2剂TAF/EVG栓剂后72小时内采集血液、直肠液和直肠组织。
主要发现
- TAF/EVG栓剂安全且耐受良好。
- 血浆中EVG和TFV浓度低:2剂次后中位峰值浓度EVG为2.4 ng/mL,TFV为4.4 ng/mL。
- 直肠组织EVG在2小时达峰(2剂次中位数9 ng/mg),但24小时时多数样本降至定量下限以下,而TFV-DP在2剂次后72小时内维持>2000 fmol/百万细胞。
- 与基线相比,离体直肠组织HIV感染的中位累积log10 HIV p24抗原在1剂和2剂后各时间点均降低(P < .065和P < .039)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On-demand topical products could be an important tool for human immunodeficiency virus (HIV) prevention. We evaluated the safety, pharmacokinetics, and ex vivo pharmacodynamics of a tenofovir alafenamide/elvitegravir (TAF/EVG, 20 mg/16 mg) insert administered rectally. METHODS: MTN-039 was a phase 1, open-label, single-arm, 2-dose study. Blood, rectal fluid, and rectal tissue were collected over 72 hours following rectal administration of 1 and 2 TAF/EVG inserts for each participant. RESULTS: TAF/EVG inserts were safe and well tolerated. EVG and tenofovir (TFV) were detected in blood plasma at low concentrations: median peak concentrations after 2 inserts were EVG 2.4 ng/mL and TFV 4.4 ng/mL. Rectal tissue EVG peaked at 2 hours (median, 2 inserts = 9 ng/mg) but declined to below limit of quantification in the majority of samples at 24 hours, whereas tenofovir diphosphate (TFV-DP) remained high >2000 fmol/million cells for 72 hours with 2 inserts. Compared to baseline, median cumulative log10 HIV p24 antigen of ex vivo rectal tissue HIV infection was reduced at each time point for both 1 and 2 inserts (P < .065 and P < .039, respectively). DISCUSSION: Rectal administration of TAF/EVG inserts achieved high rectal tissue concentrations of EVG and TFV-DP with low systemic drug exposure and demonstrable ex vivo inhibition of HIV infection for 72 hours. Clinical Trials Registration . NCT04047420.
引用
- Riddler SA, Kelly CW, Hoesley CJ, et al. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis. 2024. PMID: 38655842. doi:10.1093/infdis/jiae211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。